AzTrials
AzTrials

Apical PeriodontitisNCT07173725

The Effect of Using Octenidine Hydrochloride as a Final Irrigation Solution on Teeth With Asymptomatic Apical Periodontitis on Postoperative Pain and Treatment Success: A Prospective Randomized Clinical Study

A study testing Octenidine dihydrochloride 0.1% and Chlorhexidine 2% in people with Apical Periodontitis and Postoperative Pain, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This single-centre, randomized, parallel-group clinical trial compared two commonly used final irrigants in single-visit root canal treatment: octenidine dihydrochloride (OCT) and chlorhexidine (CHX). Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Apical Periodontitis, Postoperative Pain
What is being tested?
Octenidine dihydrochloride 0.1% and Chlorhexidine 2%
Could I receive a placebo?
No, everyone receives an active treatment
How many people
142 participants
Where
1 siteTurkey (Türkiye)
Study dates
8 Mar 2023to 20 Jul 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 to 65 years (inclusive)
  • Single-rooted, single-canal tooth
  • Diagnosis of asymptomatic apical periodontitis on periapical radiographs
  • Able and willing to provide written informed consent
  • Able to complete a 48-hour pain diary (6 h, 12 h, 24 h, 48 h)

Who cannot join

  • Symptomatic apical periodontitis or acute apical abscess
  • Previous root canal treatment of the study tooth
  • Systemic condition requiring antibiotic prophylaxis or that interferes with pain assessment
  • Pregnancy or lactation
  • Known allergy or contraindication to study irrigants/materials
  • Use of analgesics or anti-inflammatory drugs within 12 hours before treatment
  • Inability to comply with study procedures
  • More than one eligible tooth (one patient = one tooth rule; a pre-specified index tooth is selected)

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Bezmialem Vakif University Dental Hospital - Department of Endodontics

    Istanbul, 34093

Other trials in Turkey (Türkiye)

About this study

Official title: Octenidine Versus Chlorhexidine as the Final Irrigant in Single-visit Endodontics: a Randomized Clinical Trial of Early Postoperative Pain

This single-centre, randomized, parallel-group clinical trial compared two commonly used final irrigants in single-visit root canal treatment: octenidine dihydrochloride (OCT) and chlorhexidine (CHX). Adults with single-rooted, single-canal teeth diagnosed with asymptomatic apical periodontitis were treated in one visit under local anaesthesia and rubber-dam isolation. After shaping with sodium hypochlorite and smear-layer removal with EDTA, the assigned final irrigant was delivered and sonically activated. In both groups, OCT 0.1 percent or CHX 2 percent was activated using three 20-second cycles, and the solution was refreshed with 2 mL between cycles (approximate total 6 mL). Postoperative pain was recorded by participants on an 11-point Numeric Rating Scale (0 = no pain, 10 = worst pain) at 6, 12, 24, and 48 hours. The primary outcome was pain at 48 hours. Secondary outcomes were pain at earlier time points, use of rescue analgesics within 0-48 hours, and unplanned urgent care within 48 hours. The aim was to determine whether OCT reduces early postoperative pain compared with CHX when used as the final irrigant in single-visit endodontics.

Read the detailed description

Design and setting. Prospective, randomized, parallel-group, blinded clinical trial conducted at a university dental hospital (Istanbul, Turkey). All treatments were completed in a single visit by an experienced endodontist using local anaesthesia and rubber-dam isolation.

Participants. Adults (18 years or older) with single-rooted, single-canal teeth diagnosed with asymptomatic apical periodontitis on periapical radiographs were eligible. Exclusion criteria included symptomatic apical periodontitis or acute abscess, previous root-canal treatment of the study tooth, systemic conditions interfering with pain assessment or requiring antibiotic prophylaxis, pregnancy or lactation, known allergy to study materials, and use of analgesics or anti-inflammatory drugs within 12 hours before treatment. One patient contributed one tooth.

Randomization, allocation concealment, and masking. Participants were randomized 1:1 to OCT or CHX using computer-generated permuted blocks with stratification by baseline pain (NRS <= 3 vs > 3). Allocation was concealed with sequentially numbered, opaque, sealed envelopes. Irrigants were prepared by a third party in identical opaque syringes labelled A/B. Participants, the care provider (operator), and the outcomes assessor were blinded until database lock.

Interventions. Working length was established with an electronic apex locator and confirmed radiographically when needed. Root canals were prepared with nickel-titanium rotary instruments to size 40/0.04. During shaping, 5.25 percent sodium hypochlorite was used (approximately 2 mL after each instrument change). The smear layer was removed with 17 percent EDTA (about 10 mL) activated with a sonic device, followed by saline. For the final irrigation, the allocated solution was delivered and sonically activated using the same protocol in both groups: OCT 0.1 percent or CHX 2 percent, activated in three 20-second cycles with the solution refreshed with 2 mL between cycles (approximate total 6 mL). A side-vented needle was placed short of the working length. Root-canal obturation was completed in the same session using gutta-percha and an epoxy resin-based sealer with cold lateral compaction. Access cavities were restored with a resin composite. Rescue analgesics were permitted as needed and recorded by patients.

Outcomes. Primary outcome: patient-reported pain on the 0-10 NRS at 48 hours after treatment. Secondary outcomes: NRS pain at 6, 12, and 24 hours; total rescue analgesic consumption from 0 to 48 hours; and unplanned urgent care or adverse events within 48 hours.

Sample size and analysis plan. The a priori sample-size calculation assumed a between-group difference of 1.0 NRS unit (SD 2.0), alpha 0.05, and power 0.80, yielding 100 participants; allowing for attrition, the target was 120. Analyses compared groups at 48 hours and evaluated pain trajectories over time using mixed-effects methods with fixed effects for group and time and a random intercept for participant. Two-sided p < 0.05 was considered statistically significant.

Oversight. The protocol was approved by the Bezmialem Vakif University Clinical Research Ethics Committee (approval E.99606). The trial was conducted in accordance with the Declaration of Helsinki.

Being tested
Octenidine dihydrochloride 0.1%, Chlorhexidine 2%
Keywords
Endodontics, Root canal treatment, Final irrigant, Single-visit endodontics, Chlorhexidine, Octenidine
Medical subject headings
Periapical Periodontitis, Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Octenidine dihydrochloride 0.1%Drug

    Also called OCT; Octenidine 0.1% solution

    Final intracanal irrigant (aqueous solution); single administration during the final irrigation phase. Sonic activation performed in three 20-second cycles; solution refreshed with 2 mL between cycles (approximate total 6 mL per canal). Delivered through a side-vented needle positioned short of the working length.

  • Chlorhexidine 2%Drug

    Also called CHX; Chlorhexidine 2% solution

    Final intracanal irrigant (aqueous solution); single administration during the final irrigation phase. Sonic activation performed in three 20-second cycles; solution refreshed with 2 mL between cycles (approximate total 6 mL per canal). Delivered through a side-vented needle positioned short of the working length.

Study groups in NCT07173725
Study groupRoleWhat they receive
Octenidine 0.1% final irrigantExperimentalSingle-visit root canal treatment with octenidine dihydrochloride 0.1% as the final irrigant. The irrigant was sonically activated using three 20-second cycles; the solution was refreshed with 2 mL between cycles (approximate total 6 mL). Delivery through a side-vented needle positioned short of the working length. The final irrigant was administered once, during the final irrigation phase. All other procedural steps were identical to the comparator arm.
Receives: Drug: Octenidine dihydrochloride 0.1%
Chlorhexidine 2% final irrigantActive comparatorSingle-visit root canal treatment with chlorhexidine 2% as the final irrigant. The irrigant was sonically activated using the same protocol as the experimental arm: three 20-second cycles with the solution refreshed with 2 mL between cycles (approximate total 6 mL). Delivery through a side-vented needle positioned short of the working length. The final irrigant was administered once, during the final irrigation phase. All other procedural steps were identical to the experimental arm.
Receives: Drug: Chlorhexidine 2%

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain at 48 hours (NRS 0-10)

    Patient-reported pain on the 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst pain). Higher scores indicate worse pain. Assessed using a patient diary. Analysis compares OCT vs CHX at 48 hours; analysis population includes all randomized participants with an available 48 h NRS value.

    Measured: 48 hours after treatment

Secondary outcomes (6)
  1. Pain at 6 hours (NRS 0-10)

    Patient-reported NRS pain score (0 = no pain, 10 = worst pain). Higher scores indicate worse pain. Assessed using a patient diary; between-group comparison at 6 hours.

    Measured: 6 hours after treatment

  2. Pain at 12 hours (NRS 0-10)

    Patient-reported NRS pain score (0 = no pain, 10 = worst pain). Higher scores indicate worse pain. Assessed using a patient diary; between-group comparison at 12 hours.

    Measured: 12 hours after treatment

  3. Pain at 24 hours (NRS 0-10)

    Patient-reported NRS pain score (0 = no pain, 10 = worst pain). Higher scores indicate worse pain. Assessed using a patient diary; between-group comparison at 24 hours.

    Measured: 24 hours after treatment

  4. Rescue analgesic consumption (0-48 hours)

    Number of self-reported rescue analgesic doses taken from 0 to 48 hours after treatment (any medication allowed per routine care). Participants recorded type, dose, and timing in a diary. Higher counts indicate greater analgesic use.

    Measured: 0 to 48 hours after treatment

  5. Unplanned urgent care within 48 hours

    Count of participants who required unplanned urgent dental care (eg, unscheduled clinic visit or phone consultation requiring prescription) within 48 hours after treatment. Reported as number and proportion of participants.

    Measured: Up to 48 hours after treatment

  6. Adverse events within 48 hours (postoperative flare-up and other events)

    Occurrence of any adverse event within 48 hours after treatment, including postoperative flare-up requiring unplanned care. Reported as number and proportion of participants with at least one event; serious and non-serious events summarized separately.

    Measured: Up to 48 hours after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2025
  2. Study start8 Mar 2023
  3. Primary completion18 Oct 2024
  4. Study completion20 Jul 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized, parallel-group, single-centre endodontic trial; single-visit treatment; final irrigant: octenidine vs chlorhexidine.
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
142 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07173725
Sponsor's protocol ID
08.03.2023-E.99606
Status last verified
Sep 2025
First submitted
8 Sep 2025
Last updated
15 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Octenidine dihydrochloride 0.1% and Chlorhexidine 2% in people with Apical Periodontitis and Postoperative Pain, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain at 48 hours (NRS 0-10) (time frame: 48 hours after treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in